Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Zevra Therapeutics (ZVRA) Times Interest Earned (2016 - 2025)

Historic Times Interest Earned for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to $2.02.

  • Zevra Therapeutics' Times Interest Earned rose 11710.33% to $2.02 in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.66, marking a year-over-year increase of 2732.1%. This contributed to the annual value of -$11.84 for FY2024, which is 6418.61% up from last year.
  • Zevra Therapeutics' Times Interest Earned amounted to $2.02 in Q3 2025, which was up 11710.33% from -$35.36 recorded in Q2 2025.
  • In the past 5 years, Zevra Therapeutics' Times Interest Earned registered a high of $364.56 during Q2 2021, and its lowest value of -$689.31 during Q2 2022.
  • In the last 5 years, Zevra Therapeutics' Times Interest Earned had a median value of -$31.74 in 2023 and averaged -$103.52.
  • Within the past 5 years, the most significant YoY rise in Zevra Therapeutics' Times Interest Earned was 1672920.6% (2021), while the steepest drop was 3540681.51% (2021).
  • Zevra Therapeutics' Times Interest Earned (Quarter) stood at -$568.4 in 2021, then soared by 90.54% to -$53.78 in 2022, then surged by 62.72% to -$20.05 in 2023, then skyrocketed by 64.95% to -$7.03 in 2024, then surged by 128.75% to $2.02 in 2025.
  • Its last three reported values are $2.02 in Q3 2025, -$35.36 for Q2 2025, and -$2.72 during Q1 2025.